8-K: AdaptHealth Reports Q2 2026 Results, Divests Diabetes Business

AdaptHealth Corp. announced its second quarter 2026 financial results, reporting a net loss and lowering its full-year outlook, while also detailing the divestiture of its Diabetes Health business.

Summary

• AdaptHealth Corp. reported a net loss of $145.3 million for the second quarter of 2026, a significant shift from a net income of $4.2 million in the prior year's quarter.
• The company experienced a substantial goodwill impairment charge of $144.2 million, which heavily influenced the net loss.
• Net revenue increased by 12.7% to $740.3 million, with organic revenue growth of 15.9% across all segments.
• Adjusted EBITDA decreased by 3.2% to $132.0 million compared to $136.4 million in the second quarter of 2025.
• The company has revised its full-year 2026 financial guidance downwards, citing impacts from the Diabetes Health business divestiture, West Coast capitated contract transition, and a manufacturer price increase.
• AdaptHealth is divesting its Diabetes Health business for $235.0 million in cash, a strategic move to focus on core Sleep Health, Respiratory Health, and Wellness-at-Home businesses.
• The company completed a workforce restructuring, expecting $19 million in annualized savings.
• Cash flow from operations for year-to-date 2026 was $239.0 million, down from $257.5 million in the comparable 2025 period, and free cash flow was negative $48.4 million year-to-date 2026, compared to $73.3 million in 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to a significant net loss, a substantial goodwill impairment, and a lowered financial outlook, despite some positive top-line growth and strategic divestitures.

Positives

• Net revenue grew by 12.7% to $740.3 million in the second quarter of 2026.
• Organic revenue growth was strong at 15.9%, demonstrating growth across all reportable segments.
• The company completed its first full quarter under an exclusive capitated agreement with a large national integrated delivery network, now at run-rate.
• A new capitated agreement was signed with Humana OneHome in South Florida and Texas, successfully transitioning approximately 478,000 members.
• Registered myAPP users grew to over 512,000, a 56% increase from year-end 2025, with the launch of an AI-powered mask-fitting tool.
• A workforce restructuring was completed, generating $19 million in annualized savings while maintaining operational delivery.
• The company redeemed its 6.125% Senior Notes due 2028 using proceeds from a $325 million delayed draw term loan.

Negatives

• Reported a net loss of $145.3 million for the second quarter of 2026, compared to a net income of $4.2 million in Q2 2025.
• Incurred a significant goodwill impairment charge of $144.2 million.
• Adjusted EBITDA decreased by 3.2% to $132.0 million from $136.4 million in the prior year's quarter.
• Year-to-date free cash flow turned negative at $(48.4) million, a substantial decrease from $73.3 million in the comparable period of 2025.
• The full-year 2026 financial outlook has been lowered.
• The complexity of the West Coast capitated partnership transition has impacted margins.
• An unexpected price increase from a manufacturer has added cost pressures.

Risks

• The complexity of the West Coast capitated partnership transition has impacted margins.
• An unexpected price increase from one of the manufacturers has led to cost pressures.
• The company's revised full-year outlook is subject to various factors including the impact of the Diabetes Health business divestiture, the West Coast capitated contract, and manufacturer price increases.
• Forward-looking statements are subject to risks and uncertainties, including potential judicial and administrative proceedings, changes in customer preferences, and competitive conditions in the healthcare sector.

Future Outlook

The company is revising its full-year 2026 financial guidance on a continuing operations basis. Net revenue is projected to be between $2.85 billion and $2.89 billion. Adjusted EBITDA is expected to be between $490 million and $520 million. Free cash flow is projected to be between $80 million and $120 million. The revised guidance reflects impacts from the Diabetes Health business divestiture, the West Coast capitated contract, and a manufacturer price increase.

Management Comments

• "In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business," said Suzanne Foster, Chief Executive Officer.
• "Also, in July we signed a definitive agreement to divest our Diabetes Health business, the most significant step yet in our multi-year effort to focus AdaptHealth on our core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses."
• "Our West Coast capitated partnership reached full scale in the quarter, and the complexity of that transition has impacted our margins."
• "Together with an unexpected price increase from one of our manufacturers, this has led us to lower our full-year outlook."
• "We are moving quickly to address the cost pressures introduced by our rapid growth, and we believe these actions will make us a stronger, more efficient company."

Industry Context

StockSavvy.ai notes that AdaptHealth's strategic divestiture of its Diabetes Health business aligns with a broader industry trend of companies focusing on core competencies and shedding non-essential or lower-margin segments to improve efficiency and profitability. The challenges faced with the capitated agreement and manufacturer price increases highlight the operational complexities and margin pressures common in the healthcare-at-home sector, particularly when scaling new contracts.

Stakeholder Impact

• Shareholders: The significant net loss, goodwill impairment, and lowered financial outlook are likely to negatively impact shareholder value and investor confidence in the short term.
• Employees: The workforce restructuring indicates potential impacts on employee roles and responsibilities, though the company states operational delivery is maintained.
• Customers/Patients: The focus on core businesses and the expansion of digital tools like myAPP and the AI mask-fitting tool aim to improve patient engagement and service delivery.
• Suppliers: The mention of a manufacturer price increase could indicate potential renegotiations or shifts in supplier relationships.
• Creditors: The decrease in cash flow from operations and negative free cash flow could raise concerns about the company's ability to service debt, although the company has secured new financing.

Next Steps

• Continue to focus on core Sleep Health, Respiratory Health, and Wellness-at-Home businesses following the divestiture of the Diabetes Health business.
• Address cost pressures introduced by rapid growth and operational complexities.
• Integrate the new capitated agreement with Humana OneHome in South Florida and Texas.
• Leverage the joint venture with a leading eCommerce sleep retailer to reach the undiagnosed OSA population.
• Continue to advance patient digital engagement and self-service capabilities through platforms like myAPP and AI tools.

Key Dates

Recommendation

While the company shows strong organic growth and is making strategic moves like divesting a non-core business, the significant net loss, goodwill impairment, negative free cash flow, and lowered full-year guidance warrant caution. The positive strategic actions are overshadowed by current financial performance issues. A 'hold' recommendation reflects a balanced view of the strategic repositioning against the immediate financial headwinds.

Keywords

healthcare-at-home, home medical equipment, medical supplies, Sleep Health, Respiratory Health, Wellness-at-Home, capitated agreement, goodwill impairment